Overall Score

Growth Runway

KalVista has a credible long-term growth opportunity if its lead hereditary angioedema program converts into a commercial product.

The company remains pre-profit and the current revenue base is still too small to support a high-confidence 10-year growth thesis.

Financial Strength

Liquidity is solid with a current ratio of 5.58 and cash ratio of 4.00, giving the company near-term operating flexibility.

Balance-sheet leverage appears manageable on a net basis, with net debt to EBITDA at -0.47.

Profitability

Trailing margins remain deeply negative, with operating margin at -120.8% and net margin at -119.4%.

Returns on capital are also negative, including ROIC at -46.8% and ROE at -1057.4%, indicating the business is not yet generating economic profit.

Valuation

The stock trades at a rich EV/sales multiple of 12.88 despite negative earnings and cash flow.

Negative free cash flow and negative EBITDA make traditional valuation support limited at the current stage.

Execution Risk

The company is still burning cash, with free cash flow yield at -3.9% and operating cash flow yield at -2.5%.

High R&D intensity and ongoing losses create meaningful execution risk until commercialization or partnership economics improve.